MedTrace Logo

Safety, Tolerability & PK of AZD0328 in Caucasian & Japanese

NCT00738959 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2008-10-29

No results posted yet for this study

Summary

This study will be performed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of AZD0328 when administered to Japanese and Caucasian healthy male volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

AZD0328

Oral solution A single dose Day 1 followed by once daily doses on Day 3-7

Sponsors & Collaborators

Principal Investigators

  • Didier Meulien, MD · AstraZeneca R&D Södertälje, Sweden

  • Ulrike Lorch, MD · Richmond Pharmacology Ltd St George's University of London Cranmer Terrace, TootingLondon SW17 ORE UK

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00738959 on ClinicalTrials.gov